Proof of concept study of cognitive improvement in patients with schizophrenia - HALO

Study identifier:D3690C00011

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multi-Center Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase IIb Proof of Concept Study with 3 Oral Groups of AZD3480 during 12 Weeks Treatment of Cognitive Deficits in Patients with Schizophrenia

Medical condition

schizophrenia

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD3480

Sex

All

Actual Enrollment

445

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 Aug 2007
Primary Completion Date: 01 Oct 2008
Study Completion Date: 01 Nov 2008

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2014 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria